References
- ChengJZhouTLiuC1994Protection from Fas-mediated apoptosis by a soluble form of the Fas moleculeScience26351541759627510905
- HeufelderAEJobaW2000Thyroid-associated eye diseaseStrabismus81011110980691
- KenjiOSatoAKawaguchiSHashimotoM2003Effect of steroid pulse therapy with and without orbial radiotherapy on Grave’s opthalmopathyAm J Opthalmol13528590
- KozoraELaudenslagerMLemieuxA2001Inflammatory and hormonal measures predict neuropsychological functioning in systemic lupus erythematosus and rheumatoid arthritis patientsJ Int Neuropsychol Soc77455411575596
- OhtsukaKHashimotoM2000Serum levels of soluble Fas in paitents with Graves’ophthalmopathyBr J Ophthalmol84103610611108
- ProphetHMaticGBWinklerRE2001Two cases of refractory endocrine ophthalmopathy successfully treated with extracorporeal immunoadsorptionTherapeutic Apheresis5142611354299
- SiddiqiAMonsonJPWoodDF1999Serum cytokines in thyrotoxicosisJ Clin Endocrinol Metab84435910022397
- van LopikTHartMBMBoeijeL1999Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapseJ Rheumatol266079918241
- UysalARCorapciogluDTonyukukVC1999Effect of octreotide treatment on Graves’ ophthalmopathyEndocrin J465737
- WakelkampIMGerdingMNVan Der MeerJW2000Both Th1- and Th2-derived cytokines in serum are elevated in Graves’ ophthalmopathyClin Exp Immunol121453710971510